Moderna says COVID-19 vaccine immunity to stay at least a year

The Muslim Times has the latest and the best about vaccines.

Source: New York Post

Immunity from Moderna Inc’s COVID-19 vaccine should last at least a year, the company said on Monday at the J.P. Morgan Healthcare conference.

The drugmaker said it was confident that the messenger RNA (mRNA) technology it used was well suited to deploy a vaccine based on the new variant of the coronavirus which has emerged in a handful of countries.

The company’s vaccine, mRNA-1273, uses synthetic mRNA to mimic the surface of the coronavirus and teach the immune system to recognize and neutralize it.

Moderna said in December it would run tests to confirm the vaccine’s activity against any strain.

The company said on Monday it expects to deliver between 600 million doses and 1 billion does of its vaccine in 2021 and forecast vaccine-related sales of $11.7 billion for the year, based on advance purchase agreements signed with governments.

Read further

Categories: Vaccine

5 replies

  1. (CNN) Health officials in California are telling medical providers across the state not to administer doses from one lot of Moderna’s coronavirus vaccine while they investigate possible severe allergic reactions last week in a number of people who got shots at a community vaccination clinic.

    Moderna said 37 different states got shipments from the lot, which included more than 1.2 million doses, and said most had likely been used.

    In California, more than 330,000 doses from the lot were distributed to 287 providers across the state from January 5-12. Tens of thousands of doses may have already been administered, but the number of unused doses is unknown, according to Darrel Ng, a spokesperson for the California Department of Public Health.

    CDPH said Sunday that fewer than 10 people at a clinic in San Diego who received Covid-19 shots from the lot required medical attention over the span of 24 hours. The state said it was not aware of anyone at any of the other 286 sites who had similar allergic reactions after receiving vaccine from the lot.
    California’s health department said it recommended pausing the entire lot, noting that there are not immediate replacement doses in addition to what had already been ordered.

    https://www.cnn.com/2021/01/18/health/ca-vaccine-lot-pause/index.html

  2. Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK). TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine candidate.

    “We are pleased that this Phase 1/2 study of our COVID-19 vaccine in healthy adults in Japan has begun. This is the first clinical trial of a Moderna product in Japan and we thank Takeda for partnering with us to potentially protect the Japanese population from COVID-19 with a vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna.

    This placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. Takeda intends to enroll 200 participants aged 20 years and above in Japan. Each participant will be assigned to receive a placebo or a 100 μg dose at both vaccinations. Participants will be followed through 12 months after the second vaccination. The ClinicalTrials.gov identifier is NCT04677660.

    Takeda and Moderna previously announced that Takeda will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate starting in the first half of 2021, pending licensure in Japan.

    https://finance.yahoo.com/news/moderna-announces-first-participant-dosed-140000002.html

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.